Key Highlights

  • 614.25 is the negative EPS forecast shown in the screener data for Jaguar Health, Inc. (NASDAQ:JAGX), an extreme figure flagged for review, versus -3.84 for Arrive AI, -3.33 for Creative Media, -2.5 for Tevogen and -2.35 for Inhibrx.
  • 6.44 million is the USD market Capitalization of Jaguar Health in the screener data, next to USD 4.06 million for Arrive AI Inc. (NASDAQ:ARAI) and USD 13.93 million for Creative Media, all carrying nano-cap hazards.
  • 100.56 million is the USD market capitalization of Tevogen Inc. (NASDAQ:TVGN) in the screener data, versus USD 1.33 billion for Inhibrx, although Tevogen held just USD 1.08 million of cash on June 30, 2026.
  • 2.34 is the USD loss per share Inhibrx Biosciences, Inc. (NASDAQ:INBX) booked for the second quarter, versus 4.03 at Creative Media, 1.52 at Tevogen, 0.28 at Arrive AI prior to its share consolidation plus 15.68 at Jaguar Health.

Jaguar Health, Inc. (NASDAQ:JAGX): EPS Estimate -614.25, USD 6.44 Million Market Value

Jaguar Health (NASDAQ:JAGX) holds the steepest loss forecast among these names, a consensus reading of -614.25 per share in the screener data, an extreme number that company releases leave unexplained and that appears here purely as a data point. Third quarter results are expected once trading ends on November 13, 2026, and the USD 6.44 million valuation brings nano-cap hazards. The second quarter produced a loss of USD 15.68 per share, compared with 358.94 a year before, on Revenue of USD 1.225 million, a drop of 59%. At Jaguar Health, Inc. (NASDAQ:JAGX), the operating loss shrank to USD 7.597 million from USD 8.007 million. Management expects to file the MVID application for crofelemer, a new drug, during the second three months of 2027, yet no numerical financial outlook turned up. Product sales were USD 1.182 million against USD 2.936 million, and the Future Pak licensing arrangement delivered USD 16 million upfront during the first quarter. Balances for cash and Debt did not surface in published reporting.

Arrive AI Inc. (NASDAQ:ARAI): EPS Estimate -3.84, USD 4.06 Million Market Value

Arrive AI Inc. (NASDAQ:ARAI) is slated to publish before trading opens on November 13, 2026, hosting a call at 8:30 a.m. ET, with a consensus EPS estimate of -3.84 in the screener data. Its USD 4.06 million valuation is the tiniest of the group and sits in nano-cap territory. A 1-for-48 consolidation of shares became effective on November 12, 2026, so the USD 0.28 per-share loss for the second quarter works out to roughly USD 13.44 on a split-adjusted basis, calculated, which muddies what the estimate rests on. At Arrive AI Inc. (NASDAQ:ARAI), the quarterly net loss reached USD 14.08 million, including a USD 9.70 million non-cash loss from converting notes, on revenue of merely USD 14,700. Cash totalled USD 2.98 million on June 30, 2026, along with USD 2.16 million in investments. No numerical guidance appeared, and risks involve dilution along with listing compliance. Total Assets reached USD 12.44 million, while the accumulated Deficit reached USD 49.19 million.

Creative Media & Community Trust Corporation (NASDAQ:CMCT): EPS Estimate -3.33, USD 13.93 Million Market Value

Creative Media & Community Trust (NASDAQ:CMCT) publishes before trading opens on November 13, 2026, with a consensus forecast of -3.33 per share in the screener data, narrower than the USD 4.03 diluted loss per share for the second quarter. Its valuation is USD 13.93 million, which is in nano-cap territory, and two 1-for-10 reverse splits during 2026 distort per-share comparisons across periods. Revenue for the second quarter was USD 29.683 million, flat versus USD 29.689 million, while the loss attributable to common stockholders shrank to USD 10.958 million from USD 14.279 million. At Creative Media & Community Trust Corporation (NASDAQ:CMCT), multifamily occupancy climbed to 95.3%, yet a USD 97.1 million Oakland Mortgage came due without being refinanced, based on published reporting. No numeric guidance surfaced, while the secondary figures originate from a summary that cautions it may hold errors. Office leasing sat at 72.3% and hotel RevPAR was USD 180.47 against USD 166.83. Dilution, office exposure and refinancing top the risk list, and investors should watch each one.

Tevogen Inc. (NASDAQ:TVGN): EPS Estimate -2.5, USD 100.56 Million Market Value

Tevogen Inc. (NASDAQ:TVGN) publishes once trading ends on November 13, 2026, with a consensus forecast of -2.5 for each share and a USD 100.56 million valuation in the screener data, numbers flagged as odd for a company holding USD 1.08 million in cash. That forecast runs deeper than the USD 1.52 loss per share for the second quarter, which stemmed from USD 5,761,940 of net loss. At Tevogen Inc. (NASDAQ:TVGN), liabilities totalled USD 13,616,501 against assets of USD 4,727,741, leaving the stockholders' deficit at USD 8,888,760, and USD 1,651,000 of notes payable sat in default. A Loan from a related party stood at USD 6.4 million, with USD 11.0 million still undrawn and available to the company. Management said that cash, loan capacity, plus a grant should cover a minimum of 12 months ahead, while any fresh clinical trial waits for funding. A 1-for-50 reverse split took hold on March 6, 2026, with dilution a material risk.

Inhibrx Biosciences, Inc. (NASDAQ:INBX): EPS Estimate -2.35, USD 1.33 Billion Market Value

Inhibrx Biosciences, Inc. (NASDAQ:INBX) shows the mildest loss forecast in this group, a consensus reading of -2.35 for each share in the screener data, plus easily the biggest valuation at USD 1.33 billion, with results due once trading ends on November 13, 2026. Its net loss for the second quarter was USD 36.7 million, or USD 2.34 per share, compared with USD 28.7 million and USD 1.85 one year earlier, with zero revenue, and USD 23.9 million spent on research and development. At Inhibrx Biosciences, Inc. (NASDAQ:INBX), cash reached USD 219.5 million by August 6, 2026, up from USD 133.3 million on June 30 following a USD 100.0 million loan draw. The FDA assigned a PDUFA goal date of April 14, 2027 to ozekibart. Long-term debt, net came to USD 176.3 million, alongside a shareholders' deficit of USD 53.0 million. Management supplied no clear projection for cash runway, and the INBRX-106 trial result did not surface in published reporting.

Where Things Stand

Five companies publish on November 13, 2026, with loss forecasts running from -2.35 to -614.25 per share. Jaguar Health (NASDAQ:JAGX) shows an unexplained data point and a USD 6.44 million valuation. Arrive AI Inc. (NASDAQ:ARAI) wrapped up its reverse split on November 12, 2026. Creative Media & Community Trust (NASDAQ:CMCT) confronts the Oakland mortgage. Tevogen Inc. (NASDAQ:TVGN) leans on related-party funding. Inhibrx Biosciences, Inc. (NASDAQ:INBX) holds the largest cash pile, at USD 219.5 million. Treat extreme screener figures with caution. Readers should view this piece as general information and not as a recommendation to buy or sell.